Relatlimab

Relatlimab is a monoclonal antibody designed for the treatment of melanoma.^[3][4] It is used in combination with nivolumab to treat melanoma.^[2][5]

Relatlimab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Lymphocyte activation gene-3 (LAG-3)
Clinical data
Other names	BMS-986016, relatlimab-rmbw
License data	US DailyMed: Relatlimab
Routes of administration	Intravenous
Drug class	Antineoplastic
ATC code	None
Legal status
Legal status	CA: ℞-only[1] US: ℞-only only in combination with nivolumab[2]
Identifiers
CAS Number	1673516-98-7
DrugBank	DB14851
UNII	AF75XOF6W3
KEGG	D11350
Chemical and physical data
Formula	C6472H9922N1710O2024S38
Molar mass	145288.79 g·mol−1

Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.^[2][5] It is under development by Bristol-Myers Squibb.^[2][5] It is made using Chinese hamster ovary cells.^[2]

History

As of 2018^[update], relatlimab is undergoing Phase II/III trials.^[6]

The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.^[2][5]

Names

Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).^[7][8][9]